| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to biotechnology, specifically to cell technologies and agents for reducing cell adhesion, and may be used in medicine. A method for reducing stromal cell adhesion to CD138-expressing tumour cells in tumor cells in an individual in need thereof involves administering an immunoconjugate containing the structured antibody of targeted action on CD138-expressing tumour cells and an effector molecule to said tumour cells. The structured antibody substantially consists of or comprises a CD138 antigen-binding region comprising (a) a variable region of a heavy chain comprising the amino acid residues 31-35 (CDR1), 51-68 (CDR2) and 99-111 (CDR3) SEQ ID NO:1, and (b) a variable region of a light chain comprising the amino acid residues 24-34 (CDR1), 50-56 (CDR2) and 89-97 (CDR3) SEQ ID NO:2. The method may also involve administering an additional cytotoxic agent in an amount inhibiting, delaying and/or preventing the tumour cell growth, to said tumour cells. n EFFECT: due to reducing the tumour cell adhesion, the invention allows increasing their susceptibility to the effector molecule as a part of the immunoconjugate and the agents, particularly cytotoxic agents. n 18 cl, 21 dwg |